OncoMatch

OncoMatch/Clinical Trials/NCT05401110

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Is NCT05401110 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Osimertinib and Carotuximab for non small cell lung cancer.

Phase 1RecruitingKaren Reckamp, MD, MSNCT05401110Data as of May 2026

Treatment: Osimertinib · Carotuximab — The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

Check if I qualify

Extracted eligibility criteria

Cancer type

Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: EGFR exon 19 deletion

Required: EGFR g719x

Required: EGFR l858r

Required: EGFR l861q

Disease stage

Required: Stage IV

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: EGFR tyrosine kinase inhibitor

Part I: Progressive disease on at least one prior EGFR TKI

Cannot have received: CD105 targeted antibody (carotuximab)

Prior exposure to carotuximab or any CD105 targeted antibody

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Cedars-Sinai Cancer at Beverly Hills (THO) · Beverly Hills, California
  • Cedars-Sinai Cancer at The Angeles Clinic and Research Institute · Los Angeles, California
  • Cedars-Sinai Cancer at SOCC · Los Angeles, California
  • Cedars-Sinai Medical Center · Los Angeles, California
  • Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC · Torrance, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify